- Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. Goldhirsch, Aron; Wood, William C. // JNCI: Journal of the National Cancer Institute;10/4/95, Vol. 87 Issue 19, p1441
Describes research on primary breast cancer and updates on treatment recommendations presented by the Consensus Panel in March 1992. Guidelines presented at the 1992 Conference on Adjuvant Therapy of Primary Breast Cancer; Treatment of noninvasive ductal carcinoma in situ; Surgical treatment of...
- Node negative breast cancer. O'Reilly, S.M. // BMJ: British Medical Journal (International Edition);2/10/90, Vol. 300 Issue 6721, p346
Focuses on the adjuvant systemic treatment of patients with breast cancer and negative axillary nodes after surgery. Consideration of adjuvant treatment of breast cancer; Necessity of balance of benefits and toxicity of treatment; Evaluation of chemotherapy applications.
- A surgical subculture. Starreveld, Adalei // CMAJ: Canadian Medical Association Journal;01/01/97, Vol. 156 Issue 1, p43
Editorial. Comments on the inconsistent results of the studies on the use of the breast-conserving surgery to treat breast cancer. Limited role of adjuvant treatment in reducing the rates of local recurrence; Lack of consistency in the extent of surgery and radiation therapy. Suggestions for...
- Quality--of--Life--Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. Gelher, Richard D.; Goldhirsch, Aron; Cavalli, Franco // Annals of Internal Medicine;4/15/91, Vol. 114 Issue 8, p621
Presents a study which evaluated adjuvant therapies for operable breast cancer. Methodology; Results; Discussion.
- Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Lacour, Jean; Lacour, Fanny; Spira, Alfred; Michelson, Michael; Petit, Jean-Yves; Delage, Genevieve; Sarrazin, Danielle; Contesso, Genevieve; Viguier, Jeannine // British Medical Journal (Clinical Research Edition);2/25/1984, Vol. 288 Issue 6417, p589
Investigates the value of polyadenylic-polyuridylic acid as adjuvant treatment for operable breast cancer. Increase of survival in the group given with adjuvant treatment; Relevance of the biological effects to the therapeutic action; Proof of the acid as potent modulator of both humoral and...
- The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Manders, P.; Beex, L.V.A.M. // British Journal of Cancer;9/23/2002, Vol. 87 Issue 7, p772
Studies the prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cancer research.
- Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. Budman, Daniel R.; Berry, Donald A. // JNCI: Journal of the National Cancer Institute;08/19/98, Vol. 90 Issue 16, p1205
Focuses on a study which examines the effects of adjuvant treatment of breast cancer in the United States, using the dose and dose intensity in female patients with stage II (axillary lymph node-positive) breast cancer. Information on the participants and treatment administered to them; Methods...
- Medical oncology. // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS60
Presents an abstract of the research manuscript `Changes in physical performance during adjuvant chemotherapy for breast cancer in postmenopausal women,' by J.M. Watters et al.
- Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Fairclough, Diane L.; Fetting, John H.; Cella, David; Wonson, Wendy; Moinpour, Carol M. // Quality of Life Research;Dec1999, Vol. 8 Issue 8, p723
Purpose : The objective was to compare health related quality of life (QOL) in hormone receptor negative, node-positive breast cancer patients receiving adjuvant chemotherapy to determine whether a more intensive chemotherapy regimen has an adverse effect upon QOL that is not balanced by...